Mankind Pharma and Innovent Sign a Deal for an Immunotherapy Drug in India

By Consultants Review Team Thursday, 26 December 2024

Mankind Pharma Ltd. and Innovent Biologics announced a collaboration to solely license and commercialize the cancer-treating immunotherapy medication Sintilimab in the Indian market.

According to a joint statement from the companies, this strategic partnership intends to overcome the major obstacles in cancer treatment and provide patient access to cutting-edge therapeutic choices in the area.

Innovent and Eli Lilly co-developed Sintilimab, which is marketed in China under the name TYVYT (sintilimab injectable).

"India does not approve of sintilimab. Once we have the regulator's approval to conduct such clinical trials, we will file for its regulatory approval in India early next year and finish all necessary regulatory procedures, including conducting a phase 3 clinical trial for its successful approval in India," a Mankind Pharma spokesperson stated.

Mankind Pharma will have the sole authority to register, import, market, sell, and distribute sintilimab in India as a result of the deal with Innovent. According to the announcement, Innovative will supervise the product's production and delivery, guaranteeing steady availability and adherence to strict quality requirements.

Without providing specifics, it stated that Innovent will be qualified to collect upfront, regulatory, and commercial milestone payments.

Mankind Pharma Senior President -Sales & Marketing Atish Majumdar stated, "The partnership represents more than a commercial agreement -- it is a commitment to transforming oncological care in India, making innovative treatments available to a broader patient population."

"Together, we are dedicated to improving patient care in India by making state-of-the-art treatments more accessible and affordable," stated Samuel Zhang, Chief Business Officer of Innovative Biologics.

Current Issue




🍪 Do you like Cookies?

We use cookies to ensure you get the best experience on our website. Read more...